Skip to main content
SpringerLink
Log in

Principles of Vaccination

  • Protocol
  • First Online:
Vaccine Design

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1403))

Abstract

While many of the currently available vaccines have been developed empirically, with limited understanding on how they activate the immune system and elicit protective immunity, the recent progress in basic sciences like immunology, microbiology, genetics, and molecular biology has fostered our understanding on the interaction of microorganisms with the human immune system. In consequence, modern vaccine development strongly builds on the precise knowledge of the biology of microbial pathogens, their interaction with the human immune system, as well as their capacity to counteract and evade innate and adaptive immune mechanisms. Strategies engaged by pathogens strongly determine how a vaccine should be formulated to evoke potent and efficient protective immune responses. The improved knowledge of immune response mechanisms has facilitated the development of new vaccines with the capacity to defend against challenging pathogens and can help to protect individuals particular at risk like immunocompromised and elderly populations. Modern vaccine development technologies include the production of highly purified antigens that provide a lower reactogenicity and higher safety profile than the traditional empirically developed vaccines. Attempts to improve vaccine antigen purity, however, may result in impaired vaccine immunogenicity. Some of such disadvantages related to highly purified and/or genetically engineered vaccines yet can be overcome by innovative technologies, such as live vector vaccines, and DNA or RNA vaccines. Moreover, recent years have witnessed the development of novel adjuvant formulations that specifically focus on the augmentation and/or control of the interplay between innate and adaptive immune systems as well as the function of antigen-presenting cells. Finally, vaccine design has become more tailored, and in turn has opened up the potential of extending its application to hitherto not accessible complex microbial pathogens plus providing new immunotherapies to tackle diseases such as cancer, Alzheimer’s disease, and autoimmune disease. This chapter gives an overview of the key considerations and processes involved in vaccine development. It also describes the basic principles of normal immune respoinses and its their function in defense of infectious agents by vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Zepp F (2010) Principles of vaccine design—lessons from nature. Vaccine 28 Suppl 3:C14–C24

    Google Scholar 

  2. Plotkin SL, Plotkin SA (2012) A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 6th edn. Saunders, Philadelphia, pp 1–16

    Google Scholar 

  3. Kelly DF, Rappuoli R (2005) Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv Exp Med Biol 568:217–223

    Article  PubMed  Google Scholar 

  4. Leroux-Roels G (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28 Suppl 3:C25–C36

    Google Scholar 

  5. Girard MP, Steele D, Chaignat CL et al (2006) A review of vaccine research and development: human enteric infections. Vaccine 24:2732–2750

    Article  CAS  PubMed  Google Scholar 

  6. Edwards KM, Decker MD (2008) Pertussis vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 5th edn. Elsevier, New York, pp 467–518

    Google Scholar 

  7. Bridges CB, Katz JM, Levandowski RA et al (2008) Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 5th edn. Elsevier, New York, pp 259–290

    Google Scholar 

  8. World Health Organization (2003) Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec 78:241–250

    Google Scholar 

  9. Demicheli V, Debalini MG, Rivetti A (2009) Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst Rev (1):CD000977

    Google Scholar 

  10. Fiore AE, Feinstone FM, Bell BP (2008) Hepatitis A vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 5th edn. Elsevier, New York, pp 177–204

    Google Scholar 

  11. Sutter RW, Kew OM, Cochi SL (2008) Poliovirus vaccine—live. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 5th edn. Elsevier, New York, pp 631–686

    Google Scholar 

  12. Vesikari T, Sadzot-Delvaux C, Rentier B et al (2007) Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J 26:632–638

    Article  PubMed  Google Scholar 

  13. Orme IM (2015) Tuberculosis vaccine types and timings. Clin Vaccine Immunol 22:249–257

    Article  CAS  PubMed  Google Scholar 

  14. Siegrist CA (2012) Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 6th edn. Saunders Elsevier, Philadelphia, pp 18–36

    Google Scholar 

  15. Hoebe K, Janssen E, Beutler B (2004) The interface between innate and adaptive immunity. Nat Immunol 5:971–974

    Article  CAS  PubMed  Google Scholar 

  16. Moser M, Leo O (2010) Key concepts in immunology. Vaccine 28 Suppl 3:C2–C13

    Google Scholar 

  17. Barton GM, Medzhitov R (2002) Toll-like receptors and their ligands. Curr Top Microbiol Immunol 270:81–92

    CAS  PubMed  Google Scholar 

  18. Merle NS, Noe R, Halbwachs-Mecarelli L et al (2015) Complement system part II: role in immunity. Front Immunol 6:257

    PubMed  PubMed Central  Google Scholar 

  19. Leo O, Cunningham A, Stern PL (2011) Vaccine immunology. Perspectives Vaccinol 1:25–59

    Article  Google Scholar 

  20. Smith KA (2012) Toward a molecular understanding of adaptive immunity: a chronology, part I. Front Immunol 3:369

    PubMed  PubMed Central  Google Scholar 

  21. Smith KA (2012) Toward a molecular understanding of adaptive immunity: a chronology, part II. Front Immunol 3:364

    PubMed  PubMed Central  Google Scholar 

  22. Smith KA (2014) Toward a molecular understanding of adaptive immunity: a chronology, part III. Front Immunol 5:29

    PubMed  PubMed Central  Google Scholar 

  23. Vinuesa CG, Tangye SG, Moser B et al (2005) Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 5:853–865

    Article  CAS  PubMed  Google Scholar 

  24. Eibel H, Kraus H, Sic H et al (2014) B cell biology: an overview. Curr Allergy Asthma Rep 14:434

    Article  PubMed  Google Scholar 

  25. Shapiro-Shelef M, Calame K (2005) Regulation of plasma-cell development. Nat Rev Immunol 5:230–242

    Article  CAS  PubMed  Google Scholar 

  26. Deenick EK, Hasbold J, Hodgkin PD (2005) Decision criteria for resolving isotype switching conflicts by B cells. Eur J Immunol 35:2949–2955

    Article  CAS  PubMed  Google Scholar 

  27. Gasper DJ, Tejera MM, Suresh M (2014) CD4 T-cell memory generation and maintenance. Crit Rev Immunol 34:121–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Takemori T, Kaji T, Takahashi Y et al (2014) Generation of memory B cells inside and outside germinal centers. Eur J Immunol 44:1258–1264

    Article  CAS  PubMed  Google Scholar 

  29. Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17:1055–1065

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Banatvala JE, Van DP (2003) Hepatitis B vaccine—do we need boosters? J Viral Hepat 10:1–6

    Article  CAS  PubMed  Google Scholar 

  31. Zepp F, Knuf M, Habermehl P et al (1997) Cell-mediated immunity after pertussis vaccination and after natural infection. Dev Biol Stand 89:307–314

    CAS  PubMed  Google Scholar 

  32. Mills KH, Ryan M, Ryan E et al (1998) A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66:594–602

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Schwarz TF, Leo O (2008) Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 110(3 Suppl 1):S1–S10

    Article  CAS  PubMed  Google Scholar 

  34. Leroux-Roels I, Leroux-Roels G (2009) Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 8:401–423

    Article  CAS  PubMed  Google Scholar 

  35. Fraser A, Goldberg E, Acosta CJ et al (2007) Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 3, CD001261

    PubMed  Google Scholar 

  36. Pletz MW, Maus U, Krug N et al (2008) Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32:199–206

    Article  CAS  PubMed  Google Scholar 

  37. Borrow R, Dagan R, Zepp F et al (2011) Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines 10:1621–1631

    Article  CAS  PubMed  Google Scholar 

  38. McCullers JA (2007) Evolution, benefits, and shortcomings of vaccine management. J Manag Care Pharm 13(7 Suppl B):S2–S6

    PubMed  Google Scholar 

  39. André FE (1990) Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 8 Suppl: S74–S78

    Google Scholar 

  40. Rogers LJ, Eva LJ, Luesley DM (2008) Vaccines against cervical cancer. Curr Opin Oncol 20:570–574

    Article  PubMed  Google Scholar 

  41. Brewer JM (2006) (How) do aluminium adjuvants work? Immunol Lett 102:10–15

    Article  CAS  PubMed  Google Scholar 

  42. Garçon N, Van Mechelen M, Wettendorff M (2006) Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Schijns V, O’Hagan D (eds) Immunopotentiators in modern vaccines. Elsevier Academic Press, London, pp 161–177

    Chapter  Google Scholar 

  43. Alderson MR, McGowan P, Baldridge JR et al (2006) TLR4 agonists as immunomodulatory agents. J Endotoxin Res 12:313–319

    Article  CAS  PubMed  Google Scholar 

  44. Higgins D, Marshall JD, Traquina P et al (2007) Immunostimulatory DNA as a vaccine adjuvant. Expert Rev Vaccines 6:747–759

    Article  CAS  PubMed  Google Scholar 

  45. Garçon N, Van Mechelen M (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 10:471–486

    Article  PubMed  Google Scholar 

  46. Aguilar JC, Rodríguez EG (2007) Vaccine adjuvants revisited. Vaccine 25:3752–3762

    Article  CAS  PubMed  Google Scholar 

  47. Schwendener RA (2014) Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines 2:159–182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Daudel D, Weidinger G, Spreng S (2007) Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines 6:97–110

    Article  CAS  PubMed  Google Scholar 

  49. Liniger M, Zuniga A, Naim HY (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6:255–266

    Article  CAS  PubMed  Google Scholar 

  50. Grunwald T, Ulbert S (2015) Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin Exp Vaccine Res 4:1–10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Butterfield LH (2015) Cancer vaccines. BMJ 350:h988

    Article  PubMed  PubMed Central  Google Scholar 

  52. Broide DH (2009) Immunomodulation of allergic disease. Annu Rev Med 60:279–291

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Creticos PS, Schroeder JT, Hamilton RG et al (2006) Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355:1445–1455

    Article  CAS  PubMed  Google Scholar 

  54. Silva CL, Bonato VL, dos Santos-Junior RR et al (2009) Recent advances in DNA vaccines for autoimmune diseases. Expert Rev Vaccines 8:239–252

    Article  CAS  PubMed  Google Scholar 

  55. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines. 2003 Apr;2(2):219–29

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University Medicine Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany

    Fred Zepp

Authors
  1. Fred Zepp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fred Zepp .

Editor information

Editors and Affiliations

  1. Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

    Sunil Thomas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Zepp, F. (2016). Principles of Vaccination. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1403. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3387-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3387-7_3

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3385-3

  • Online ISBN: 978-1-4939-3387-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation